Creo Medical has reported its full results covering an 18-month period to Dec-18. Through the period the company has invested strongly in three key aspects; product development, commercial roll-out and manufacturing capability. We believe the progress made through the period (and subsequently) validates Creo's investments to date and supports the on-going investment we expect the company to undertake. We maintain our Buy recommendation.
05 Apr 2019
Cenkos: Creo Medical Group Plc - Excellet
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc - Excellet
Creo Medical Group Plc (CREO:LON) | 34.2 -0.2 (-1.4%) | Mkt Cap: 123.8m
- Published:
05 Apr 2019 -
Author:
Chris Donnellan -
Pages:
15
Creo Medical has reported its full results covering an 18-month period to Dec-18. Through the period the company has invested strongly in three key aspects; product development, commercial roll-out and manufacturing capability. We believe the progress made through the period (and subsequently) validates Creo's investments to date and supports the on-going investment we expect the company to undertake. We maintain our Buy recommendation.